发布求助
文献互助 智能选刊 最新文献

Annals of allergy最新文献

筛选
英文 中文
Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis. 每日一次丙酸氟替卡松鼻内对常年性变应性鼻炎有效。
Annals of allergy Pub Date : 1994-09-01
C H Banov, T R Woehler, C F LaForce, D S Pearlman, M N Blumenthal, W F Morgan, H Frazer, D L Southern, B Gold, E Field
{"title":"Once daily intranasal fluticasone propionate is effective for perennial allergic rhinitis.","authors":"C H Banov,&nbsp;T R Woehler,&nbsp;C F LaForce,&nbsp;D S Pearlman,&nbsp;M N Blumenthal,&nbsp;W F Morgan,&nbsp;H Frazer,&nbsp;D L Southern,&nbsp;B Gold,&nbsp;E Field","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The efficacy of intranasal fluticasone propionate 200 micrograms once daily or 100 micrograms twice daily in treating perennial allergic rhinitis was evaluated in a randomized, double-blind, placebo-controlled study of 24 weeks' duration in 365 patients. Clinician-rated and patient-rated total nasal symptom severity scores were improved within 1 week of treatment with either regimen of fluticasone propionate and improvement was maintained over the 24-week treatment period. Clinician-rated overall evaluation indicated a significantly better response in the two fluticasone propionate groups compared with the placebo group. All efficacy evaluations indicated no difference in response between the fluticasone propionate 200 micrograms once-daily and 100 micrograms twice-daily groups. Patients in both fluticasone propionate groups had significantly less nasal obstruction upon awakening than the placebo group at all assessment periods. Fewer patients in either fluticasone propionate group used antihistamine rescue medication compared with the placebo group. The percentage of patients with nasal eosinophils and basophils at the end of the 24-week treatment period was significantly lower in both fluticasone propionate groups compared with the placebo group. Safety evaluations indicated that intranasal fluticasone propionate was as safe as placebo when given as 200 micrograms once daily or 100 micrograms twice daily. The incidence of drug-related adverse events was similar among the fluticasone propionate and placebo groups except for the incidence of epistaxis and blood in nasal mucus which was somewhat higher in the fluticasone propionate twice-daily group. There was no changes in the opthalmic examinations to suggest corticosteriod-induced posterior subcapsular cataract formation.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"240-6"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19085964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions. 顺铂过敏反应的诊断及预处理在预防复发性过敏反应中的价值。
Annals of allergy Pub Date : 1994-09-01
A Goldberg, M M Altaras, Y A Mekori, Y Beyth, R Confino-Cohen
{"title":"Anaphylaxis to cisplatin: diagnosis and value of pretreatment in prevention of recurrent allergic reactions.","authors":"A Goldberg,&nbsp;M M Altaras,&nbsp;Y A Mekori,&nbsp;Y Beyth,&nbsp;R Confino-Cohen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Two patients, who developed anaphylaxis to cisplatin, are described. This phenomenon was preceded by mild allergic symptoms, which were overlooked, in previous treatment courses. Intradermal skin tests were both sensitive and specific in the diagnosis of cisplatin allergy. Pretreatment with antihistamines and corticosteroids was ineffective in preventing recurrent anaphylaxis. Thus, a trial of desensitization is mandatory among those patients whose disease responds to the administration of this agent.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"271-2"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18914221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Length of postexercise assessment in the determination of exercise-induced bronchospasm. 运动后评估长度在确定运动性支气管痉挛中的作用。
Annals of allergy Pub Date : 1994-09-01
D S Brudno, J M Wagner, N T Rupp
{"title":"Length of postexercise assessment in the determination of exercise-induced bronchospasm.","authors":"D S Brudno,&nbsp;J M Wagner,&nbsp;N T Rupp","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Exercise challenges were performed on 397 middle and high school athletes to detect unrecognized exercise-induced bronchospasm. All challenges were completed by a standard treadmill protocol and spirometry was performed prior to exercise and at 1, 10, 20, and 30 minutes after completion of the treadmill regimen. Using FEV1 as the diagnostic standard, we compared the number of students who had initial decreases of > or = 10%, > or = 15%, or > or = 20% at each of the four postexercise spirometric evaluations. FEV1 thresholds of > or = 10%, > or = 15%, and > or = 20%, when analyzed, identified 187, 125, and 90 subjects respectively with a positive response. The majority of those with a positive response were identified soon after completion of the exercise provocation; however, a larger than expected number of athletes had their initial drop in FEV1 > or = 20 minutes after cessation of exercise. This represented 9% to 14% of the total number of responders to exercise challenge. Protocols for evaluation of exercise-induced bronchospasm may need to be designed to include data points up to or beyond 30 minutes after exercise to avoid missing the late appearance of bronchospasm.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"227-31"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19085961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tosyl arginine methyl ester induces bronchoconstriction in rabbit bronchial tissues in vitro: a possible new mediator in asthma. Tosyl精氨酸甲酯体外诱导兔支气管组织收缩:一种可能的哮喘新介质。
Annals of allergy Pub Date : 1994-09-01
A H Subratty, L H Kok-Shun, M Y Yan, N Fakim
{"title":"Tosyl arginine methyl ester induces bronchoconstriction in rabbit bronchial tissues in vitro: a possible new mediator in asthma.","authors":"A H Subratty,&nbsp;L H Kok-Shun,&nbsp;M Y Yan,&nbsp;N Fakim","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Tosyl arginine methyl ester induced bronchoconstriction in rabbit bronchial rings mounted in vitro with a calculated EC50 of 5.6 x 10(-5) M as compared with acetylcholine which induced sustainable constriction with an EC50 of 2.5 x 10(-6) M. Tosyl arginine methyl ester, however, had definite bronchoconstricting properties though less potent than acetylcholine. We concluded that our data support the hypothesis that tosyl arginine methyl ester could be a possible biochemical mediator of airway contraction.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"269-70"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19085897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infection as a cause of asthma. 感染是引起哮喘的原因。
Annals of allergy Pub Date : 1994-09-01
D L Hahn
{"title":"Infection as a cause of asthma.","authors":"D L Hahn","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"276"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19085900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monthly bibliography tracks worldwide AIDS research. 每月参考书目跟踪全球艾滋病研究。
Annals of allergy Pub Date : 1994-09-01
{"title":"Monthly bibliography tracks worldwide AIDS research.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 3","pages":"A32-56"},"PeriodicalIF":0.0,"publicationDate":"1994-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19085955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum sickness-like illness associated with rifampicin. 与利福平相关的血清疾病样疾病。
Annals of allergy Pub Date : 1994-08-01
F M Parra, M J Pérez Elias, M Cuevas, A Ferreira
{"title":"Serum sickness-like illness associated with rifampicin.","authors":"F M Parra,&nbsp;M J Pérez Elias,&nbsp;M Cuevas,&nbsp;A Ferreira","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We describe a patient with human immunodeficiency virus infection who developed the main clinical features of a serum sickness reaction while receiving treatment with daily therapeutic doses of tuberculostatic drugs. A decrease in complement titers as well as a detection of significant levels of circulating immune complexes were observed. A positive skin test result was observed six hours after an intradermal test with rifampicin. No immunoglobulin or complement deposition was observed by direct immunofluorescence of a punch biopsy specimen from the cutaneous lesion.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 2","pages":"123-5"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19060761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In vivo and in vitro characterization of Allpyral grass pollen extracts. 全孢草花粉提取物的体内外特性研究。
Annals of allergy Pub Date : 1994-08-01
T R Kordash, M J Amend, L L Freshwater, R E Baker
{"title":"In vivo and in vitro characterization of Allpyral grass pollen extracts.","authors":"T R Kordash,&nbsp;M J Amend,&nbsp;L L Freshwater,&nbsp;R E Baker","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) has developed methodology to standardize both aqueous and freeze-dried (lyophilized) extracts. Thus far, it has not been determined whether or not this methodology can be used to standardize alum-adsorbed extracts. This study was designed to examine the in vivo and in vitro potency of selected Allpyral grass pollen extracts, including timothy, orchard grass, perennial ryegrass, sweet vernalgrass, and meadow fescue. Puncture testing was performed on highly grass-sensitive subjects with the concentrate of each of the five Allpyral grass extracts. Additionally, puncture testing was done on 22 subjects to compare Allpyral timothy grass with a lyophilized, standardized timothy grass extract. The ID50EAL (Intradermal Dilution for 50 mm sum of Erythema determines the Allergy Unit) skin test method was used to determine allergy units of the Allpyral extracts. Relative potency of the Allpyral timothy extracts to a timothy laboratory standard was determined using an ELISA-inhibition assay. Intradermal tests were also performed to examine the potency of the supernatant obtained after centrifugation of the whole Allpyral timothy extract. The puncture test responses to the Allpyral timothy extracts were less than those to the lyophilized extract. Those 10,000 PNU/mL Allpyral grass pollen extracts tested were determined to contain a calculated 10,000 BAU/mL. By ELISA inhibition, the Allpyral timothy extracts were determined to be approximately 1,000-fold less potent than the laboratory standard. The estimated concentration of the supernatant preparation to elicit a target response was notably (mean = 1,175 times) greater than that of the whole Allpyral timothy extract needed to elicit the same erythema response.(ABSTRACT TRUNCATED AT 250 WORDS)</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 2","pages":"127-33"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19060762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Practicing allergy with universal health insurance: the Hawaii experience. 用全民健康保险练习过敏:夏威夷的经历。
Annals of allergy Pub Date : 1994-08-01
J T McDonnell, R E Ando
{"title":"Practicing allergy with universal health insurance: the Hawaii experience.","authors":"J T McDonnell,&nbsp;R E Ando","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 2","pages":"85-7"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19061287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis. 丙酸氟替卡松鼻喷雾剂治疗豚草变应性鼻炎的多中心试验。
Annals of allergy Pub Date : 1994-08-01
J Dolovich, A G Wong, W B Chodirker, M A Drouin, F E Hargreave, J Hebert, A Knight, P Small, W H Yang
{"title":"Multicenter trial of fluticasone propionate aqueous nasal spray in ragweed allergic rhinitis.","authors":"J Dolovich,&nbsp;A G Wong,&nbsp;W B Chodirker,&nbsp;M A Drouin,&nbsp;F E Hargreave,&nbsp;J Hebert,&nbsp;A Knight,&nbsp;P Small,&nbsp;W H Yang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 4-week multicenter, double-blind, placebo-controlled, parallel-group trial was carried out with 416 adults with ragweed allergic rhinitis to compare 200 micrograms of fluticasone propionate once daily and 100 micrograms of fluticasone propionate twice daily with placebo. Compared with placebo, both groups receiving fluticasone propionate had greater number of symptom free days (P < .01), lower median symptom scores (P < .01), and greater number of days not requiring rescue medications (P < .001). No significant differences for individual symptoms were found between the two fluticasone propionate groups except that those taking the twice daily dosage used less antihistamine (P < .01) and had greater number of days free of rescue medications (P < .05). Adverse events were comparable between the three groups. These results indicate that topical intranasal fluticasone propionate 200 micrograms once daily and 100 micrograms twice daily are both efficacious and well tolerated.</p>","PeriodicalId":7931,"journal":{"name":"Annals of allergy","volume":"73 2","pages":"147-53"},"PeriodicalIF":0.0,"publicationDate":"1994-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"19060764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信